As previously reported, Leerink upgraded NeoGenomics (NEO) to Outperform from Market Perform with a price target of $25, up from $12. The company delivers on its one-stop shop business model in oncology diagnostics and is getting back on track, in the firm’s view, with strong momentum, profitability, and attractive valuation that cannot be ignored.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO: